Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Neutral

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Strong Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Oncocyte Corporation Common Stock (OCX)

In Vitro & In Vivo Diagnostic Substances

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

15 CUSHING
IRVINE, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/30/2015

Market Cap

40,639,936

Shares Outstanding

8,260,000

Weighted SO

8,260,762

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

BNR --.--%

STIM --.--%

DRIO --.--%

GTH --.--%

SERA --.--%

OLK --.--%

FONR --.--%

CSTL --.--%

XGN --.--%

Beta

0.9810

Last Div

0.0000

Range

2.08-4.34

Chg

0.0900

Avg Vol

37174

Mkt Cap

40639936

Exch

NASDAQ

Country

US

Phone

949 409 7600

DCF Diff

1.8010

DCF

0.7290

Div Yield

0.0000

P/S

39.7262

EV Multiple

-3.3758

P/FV

1.7233

Div Yield %

0.0000

P/E

-1.0826

PEG

-0.0625

Payout

0.0000

Current Ratio

1.3848

Quick Ratio

1.3848

Cash Ratio

1.2859

DSO

30.3275

DIO

0.0003

Op Cycle

30.3277

DPO

267.2344

CCC

-236.9067

Gross Margin

-0.4032

Op Margin

-22.4438

Pretax Margin

-35.3275

Net Margin

-35.3275

Eff Tax Rate

-0.2676

ROA

-0.4837

ROE

-1.4065

ROCE

-0.3400

NI/EBT

1.0000

EBT/EBIT

1.5740

EBIT/Rev

-22.4438

Debt Ratio

0.0491

D/E

0.1615

LT Debt/Cap

0.1041

Total Debt/Cap

0.1391

Int Coverage

-80.8451

CF/Debt

-4.5348

Equity Multi

3.2912

Rec Turnover

12.0353

Pay Turnover

1.3658

Inv Turnover

999999.9999

FA Turnover

0.1723

Asset Turnover

0.0137

OCF/Share

-1.2921

FCF/Share

-1.3306

Cash/Share

0.7192

OCF/Sales

-16.2551

FCF/OCF

1.0298

CF Coverage

-4.5348

ST Coverage

-16.1604

CapEx Coverage

-33.5262

Div&CapEx Cov

-33.5262

P/BV

1.7233

P/B

1.7233

P/S

39.7262

P/E

-1.0826

P/FCF

-2.3731

P/OCF

-2.3528

P/CF

-2.3528

PEG

-0.0625

P/S

39.7262

EV Multiple

-3.3758

P/FV

1.7233

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Oct 02, 22:41 Oncocyte Signs Leading Transplant Centers in US and Germany GlobeNewswire Inc. Oct 02, 22:35 Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules GlobeNewswire Inc. Nov 03, 08:30 Oncocyte to Announce Third Quarter 2023 Financial Results

Revenue Product Segmentation